ACOG trades 64.6% below Wall Street's consensus target of $13.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ACOG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Alpha Cognition Inc. Common Stock (ACOG) has a Wall Street consensus price target of $13.00, based on estimates from 1 covering analysts. With the stock currently trading at $7.90, this represents a potential upside of +64.6%. The company has a market capitalization of $123M.
Analyst price targets range from a low of $12.00 to a high of $14.00, representing a 15% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACOG trades at a trailing P/E of -6.8x. Analysts expect EPS to grow -16.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AVXLAnavex Life Sciences Corp. | $247M | $2.66 | $11.00 | +313.5% | Buy | — | 13 |
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
PRAXPraxis Precision Medicines, Inc. | $9.1B | $313.50 | $589.00 | +87.9% | Buy | — | 16 |
ACIUAC Immune S.A. | $255M | $2.51 | $7.00 | +178.9% | Buy | — | 9 |
BIIBBiogen Inc. | $30.8B | $208.46 | $218.32 | +4.7% | Buy | 14.4x | 48 |
LLYEli Lilly and Company | $1.1T | $1200.06 | $1269.94 | +5.8% | Buy | 32.8x | 45 |
PTGXProtagonist Therapeutics, Inc. | $8.5B | $131.50 | $117.25 | -10.8% | Buy | 33.0x | 26 |
AXSMAxsome Therapeutics, Inc. | $12.5B | $242.60 | $262.38 | +8.2% | Buy | — | 26 |
IQVIQVIA Holdings Inc. | $35.0B | $205.97 | $222.40 | +8.0% | Buy | 16.1x | 44 |
CRLCharles River Laboratories International, Inc. | $11.1B | $231.43 | $222.11 | -4.0% | Buy | 20.9x | 37 |
Quick answers to the most common questions about buying ACOG stock.
The consensus Wall Street price target for ACOG is $13, representing 64.6% upside from the current price of $7.9. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ACOG has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $13 implies 64.6% upside from current levels.
ACOG's current price is $7.9 with a consensus target of $13 (64.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $14 for ACOG, while the most conservative target is $12. The consensus of $13 represents the median expectation. These targets typically reflect 12-month expectations.
ACOG is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ACOG stock forecast based on 1 Wall Street analysts shows a consensus price target of $13, with estimates ranging from $12 (bear case) to $14 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ACOG, with a "Buy" consensus rating and $13 price target (64.6% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ACOG analyst price targets range from $12 to $14, a 15% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.